# To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.

> **NCT05196295** · PHASE1 · UNKNOWN · sponsor: **HoHo Biotech** · enrollment: 30 (estimated)

## Conditions studied

- Autoimmune Diseases
- Metabolic Disease

## Interventions

- **DRUG:** Hydrogen

## Key facts

- **NCT ID:** NCT05196295
- **Lead sponsor:** HoHo Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-11
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196295, "To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05196295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*